Chang H. Park
发表
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
L. Lam,
C. Tse,
Cheol‐Min Park,
2013,
Nature Medicine.
Ahmad Y. Sheikh,
Richard S. Hong,
Geoff G. Z. Zhang,
2021,
Molecular Cancer Therapeutics.
L. Lam,
J. Leverson,
S. Tahir,
2017,
BMC Cancer.
L. Lam,
J. Leverson,
S. Tahir,
2017,
BMC Cancer.
Jun Chen,
Saul H Rosenberg,
Xiaohong Song,
2010,
Bioorganic & medicinal chemistry letters.
Chang H. Park,
Chaehwa Park,
W. Choi,
2007,
Cancer research and treatment : official journal of Korean Cancer Association.